Sign up
Pharma Capital
EPIC: AHZ
Market: ASX
52-week High/Low: A$0.40 / A$0.14
Sector: Pharma & Biotech
Market Cap: A$38.34M
Website: www.admedus.com
Admedus Ltd (ASX:AHZ) is a diversified healthcare company.

 

Admedus Ltd

www.admedus.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Admedus Ltd

Admedus Ltd Snapshot

Admedus is a global healthcare company that develops, commercialises and distributes next generation medical technologies and devices. Our mission is to provide patients around the world with a better quality of life through access to our leading medical solutions and products.

Our Science

ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth.

Our clinically superior ADAPT® products are the only ones to have achieved nine years without calcification or degradation.

With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.

ADAPT® products are sold globally under the product names CardioCel®, CardioCel Neo®, CardioCel 3D®, and VascuCel® (product availability subject to regional regulatory approval).

Our flagship product, CardioCel®, is currently being used by surgeons in more than 135 global centres in Australia, Europe, US, Canada, Singapore, Malaysia, Hong Kong, India and the Middle East and North Africa Region.

All Admedus ADAPT® products are manufactured in, and distributed from, our state-of-the-art biomanufacturing facility which has substantial capacity to expand and includes an in-house research and development laboratory.

 

Last updated 19th June 2018

Wayne Paterson
President and Chief Executive Officer

Wayne Paterson has held numerous senior positions in multinational pharmaceutical companies and has lived in seven countries during the past 25 years. Throughout his career, he has been responsible for building healthcare businesses around the world, including mergers/integrations/acquisitions and major restructures. He holds an MBA from the University of Southern Queensland and a degree in business studies from the Queensland University of Technology. He also studied business courses at North Western University (Kellogg School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.


John Seaberg
Chairman

David St. Denis is an accomplished senior healthcare leader with a systematic and metrics-driven approach spanning 20 years of proven business results at the regional and global levels within the life sciences and pharmaceutical sectors. He has a Bachelor of Science from the University of Connecticut, a Masters of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College – Franklin W. Olin Graduate School of Business.


Catherine Costello
Executive Director

Catherine Costello brings more than 20 years of experience in Australian and multinational businesses and joins Admedus from an emerging ASX-listed company, where she served as Chief Financial Officer and Company Secretary.

Prior to this role, she was Group Financial Controller with a global service provider operating in 32 international jurisdictions, responsible for the global finance, reporting, tax and treasury teams.

Preceding this, she worked for US-listed entities both at the head office and regional office levels in senior financial management roles.

She has a Commerce degree from the University of Queensland, a Masters of Science from Curtin University, is a Chartered Accountant and Chartered Secretary and is a graduate of both the Australian Institute of Company Directors and the Governance Institute of Australia. She also serves on a number of community based committees.


Simon Buckingham
Non-Executive Director

Simon has more than 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. He is currently a non-executive director of several companies, as well as a Global Advisor to Swiss biotech Idorsia Pharmaceuticals Ltd.

Simon was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. He served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region.

He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served in roles in sales, marketing and development at Roche, both in Switzerland and Australia, for nine years.

He holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors.


MANAGEMENT

Wayne Paterson
President and CEO

Wayne has held numerous, senior positions in multi-national companies and has lived in seven countries during the past 25 years. Through his career, he has been responsible for building and managing multibillion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO.

From 2005 to 2013 he held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular medicine.

Between 1999 and 2005, Wayne served at Roche Pharmaceuticals where he was Head of Pharmaceuticals in Roche’s South Korean operation, following his role as Head of Commercial Operations for Roche China based in Shanghai.

From April 2015 until November 2016, Wayne served as a Non-Executive Director of Cepheid (NASDAQ: CHPD), a molecular diagnostics company based in California.
He holds an MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology.

He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.


David St Denis
Chief Operating Officer

David is an accomplished senior healthcare leader with a systematic and metrics-driven approach spanning 20 years of proven business results at the regional and global levels within the life sciences and pharmaceutical sectors.

Most recently at Merck in Germany, he headed commercial operations for Europe and Canada. He has an extensive track record in charge of complex cross-functional and multi-cultural teams that have achieved impressive business objectives in both mature markets (US, Europe, Japan) and developing markets (Brazil, Russia, India, China and Mexico).

His core competencies include operations management, strategy development, marketing and sales, new product introduction and launch excellence, market access and pricing.
David has a Bachelor of Science from the University of Connecticut, a Masters of Arts from Boston University and an MBA in Global Management and International Marketing from Babson College – Franklin W. Olin Graduate School of Business.


Catherine Costello
Chief Financial Officer

Catherine Costello brings more than 20 years of experience in Australian and multinational businesses and joins Admedus from an emerging ASX-listed company, where she served as Chief Financial Officer and Company Secretary.

Prior to this role, she was Group Financial Controller with a global service provider operating in 32 international jurisdictions, responsible for the global finance, reporting, tax and treasury teams.

Preceding this, she worked for US-listed entities both at the head office and regional office levels in senior financial management roles.

She has a Commerce degree from the University of Queensland, a Masters of Science from Curtin University, is a Chartered Accountant and Chartered Secretary and is a graduate of both the Australian Institute of Company Directors and the Governance Institute of Australia. She also serves on a number of community based committees.


Last updated 19th June 2018

Registered Office

Level 9
301 Coronation Drive
Milton, Queensland, 4064

T +61 (0)7 3152 3200
F +61 (0)7 3152 3299

Australian Customer Service:

T 1300 550 310
F 1300 880 398

Admedus Limited
ABN 35 088 221 078

Chief Executive Officer
Wayne Paterson

Chairman
John Seaberg

Non-Executive Directors
Matthew Ratty
Simon Buckingham

Company Secretary
Catherine Costello

Patent Attorney
Winthrop and Weinstein
225 S 6th St Ste 3500, Minneapolis MN 55402 . +1 (612) 604-6400

Registered Office
Level 9, 301 Coronation Drive
Milton, Queensland, 4064

Telephone:    +61 7 3152 3200
Facsimile:      +61 7 3152 3299
Email: [email protected]

Share Registry
Computershare Investor Services Pty Ltd
Level 2, Reserve Bank Building
45 St Georges Terrace
Perth, Western Australia 6000
Telephone: 1300 557 010 (within Aust) +61 3 9415 4000 (outside Aust)
Facsimile: +61 3 9473 2500

Solicitors
DLA Piper
Level 31, Central Park, 152-158 St Georges Terrace
Perth, Western Australia 6000

Auditors
HLB Mann Judd
Level 4, 130 Stirling Street
Perth, Western Australia, 6000

 
 
Last updated 19th June 2018
View full AHZ profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.